Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) SVP Amy Bachrodt sold 5,000 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $45.52, for a total transaction of $227,600.00. Following the completion of the transaction, the senior vice president directly owned 12,965 shares of the company's stock, valued at $590,166.80. The trade was a 27.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Amy Bachrodt also recently made the following trade(s):
- On Friday, January 2nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $39.15, for a total transaction of $195,750.00.
- On Monday, December 29th, Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.58, for a total transaction of $405,800.00.
- On Tuesday, December 30th, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.08, for a total transaction of $200,400.00.
Maze Therapeutics Price Performance
NASDAQ MAZE opened at $44.58 on Tuesday. The company has a market cap of $2.15 billion and a price-to-earnings ratio of -2.13. The stock's fifty day moving average price is $40.12 and its 200 day moving average price is $28.36. Maze Therapeutics, Inc. has a 1 year low of $6.71 and a 1 year high of $47.36.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.08.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in MAZE. Frazier Life Sciences Management L.P. boosted its stake in shares of Maze Therapeutics by 10.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company's stock worth $56,040,000 after acquiring an additional 438,274 shares in the last quarter. Vanguard Group Inc. raised its holdings in Maze Therapeutics by 218.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company's stock worth $34,615,000 after purchasing an additional 915,342 shares during the period. Woodline Partners LP raised its holdings in Maze Therapeutics by 10.0% in the 3rd quarter. Woodline Partners LP now owns 1,035,229 shares of the company's stock worth $26,843,000 after purchasing an additional 94,529 shares during the period. Marshall Wace LLP boosted its position in Maze Therapeutics by 3,868.5% during the third quarter. Marshall Wace LLP now owns 777,701 shares of the company's stock worth $20,166,000 after purchasing an additional 758,104 shares in the last quarter. Finally, ArrowMark Colorado Holdings LLC acquired a new stake in Maze Therapeutics in the third quarter valued at approximately $14,135,000.
Wall Street Analyst Weigh In
Several analysts have commented on MAZE shares. Guggenheim restated a "buy" rating and set a $46.00 price objective on shares of Maze Therapeutics in a research note on Friday, December 19th. Wells Fargo & Company started coverage on shares of Maze Therapeutics in a research report on Thursday, December 4th. They set an "overweight" rating and a $55.00 target price for the company. HC Wainwright increased their price target on Maze Therapeutics from $50.00 to $60.00 and gave the stock a "buy" rating in a research report on Wednesday, December 3rd. Weiss Ratings reiterated a "sell (d)" rating on shares of Maze Therapeutics in a research note on Thursday. Finally, Raymond James Financial started coverage on Maze Therapeutics in a research note on Thursday, November 13th. They issued an "outperform" rating and a $48.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $44.50.
Get Our Latest Report on Maze Therapeutics
Maze Therapeutics Company Profile
(
Get Free Report)
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
